Verisante Technology, Inc. Announces Exclusive Distribution Agreement With Clarion Medical Technologies Inc.
March 15 2012 - 10:00AM
Marketwired
Verisante Technology, Inc. (TSX
VENTURE:VRS)(OTCQX:VRSEF)(PINKSHEETS:VRSEF)(FRANKFURT:V3T) (the
"Company" or "Verisante"), a leader in cancer detection technology,
announced today that the Company has entered into an exclusive
agreement with Clarion Medical Technologies Inc. ("Clarion") to
distribute Verisante Aura(TM) in Canada.
"Clarion has broad and deep relationships with the leading
dermatologists and dermatology clinics across Canada and a wealth
of experience in introducing innovative technologies to the
dermatological industry," said Thomas Braun, President & CEO of
Verisante. "With a reputation for distributing superior products
and providing exceptional service, we believe Clarion is the ideal
partner to assist us in the sales, distribution, and servicing of
Verisante Aura(TM) within Canada."
Clarion has a current line of products that directly relate to
UV damage and skin care treatments, in addition to dermatological
products and devices utilizing optical technologies for a variety
of other medical applications, making Verisante Aura(TM) a natural
addition to this existing product line.
"Clinical study results have shown that Verisante Aura(TM) is a
device that has the potential to revolutionize the way skin cancer
is diagnosed," said Dan Webb, CEO of Clarion. "Clarion is very
excited to be the Aura's exclusive distributor in Canada and to be
able to bring this life-saving technology to medical professionals
across the country."
Verisante Aura(TM) is indicated for use for the evaluation of
skin lesions that may be clinically suspicious for melanoma,
squamous cell carcinoma and/or basal cell carcinoma when a medical
professional chooses to obtain additional information to rule out
one of the above conditions before making a final decision to
biopsy. Aura(TM) is a non-invasive optical system that uses Raman
spectroscopy to biochemically analyze the skin, providing immediate
and accurate results. The device will help to automate the current
process of diagnosis, allowing rapid scanning of the 20 to 40 skin
lesions on at-risk individuals, improving patient outcomes and
comfort.
Verisante also announced it will have an information and
education booth at the American Academy of Dermatology conference
in San Diego, CA from March 17-19 (booth #2825).
About Clarion Medical Technologies
Formerly known as Coherent-AMT, Clarion Medical Technologies
Inc. is a medical distributor of innovative technology solutions,
operating in Canada since 1989. Over that time, Clarion has gained
a superior reputation for dedication to the Canadian healthcare
community, serving Canadian hospitals and private practices with
best-in-class products, comprehensive education and business
building programs, award winning technical support and many more
unique services.
About Verisante Technology, Inc.
Verisante is a medical device company committed to
commercializing innovative systems for the early detection of
cancer. The Verisante Aura(TM) for skin cancer detection and the
Verisante Core(TM) series for lung, colon and cervical cancer
detection utilize a proprietary cancer detection platform while the
operating software and probe technology are unique to each device.
The cancer detection platform was developed by the BC Cancer Agency
and tested and refined at the Skin Care Centre at Vancouver General
Hospital. This exclusive platform technology allows Verisante to
develop and offer a range of compact, non-invasive cancer detection
devices that offer physicians immediate results for many of the
most common cancers. The Aura(TM) has been approved for sale in
Canada, Europe and Australia. The Core(TM) has not yet been
approved for sale.
Verisante Aura(TM) was recently awarded Popular Science
Magazine's "Best of What's New Award" for 2011, and Verisante
Core(TM) was named one of the top 10 cancer breakthroughs of 2011
by the Canadian Cancer Society. In addition, the Company was named
a finalist for the 2011 Regional Awards for New Technology by the
Canadian Manufacturers & Exporters and the National Research
Council of Canada and named as the year's top ranking Technology
and Life Sciences Company on the TSX Venture 50.
Website: www.verisante.com
Youtube: www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante
Forward Looking Statements
This release contains forward-looking statements, including, but
not limited to, statements regarding the future commercialization
of medical devices, the market demand for these products and the
proprietary protections the Company will obtain with regard to the
technology, all of which statements are subject to market risks,
and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These
statements are made based upon current expectations and actual
results may differ from those projected due to a number of risks
and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of
the contents of this press release. Neither the TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this press
release.
Contacts: Verisante Technology, Inc. Thomas Braun President
& CEO (604) 605-0507info@verisante.com www.verisante.com